Ascendis Pharma A/S (ASND) has released an update.
Ascendis Pharma A/S has achieved a significant milestone by obtaining marketing authorization from the UK’s MHRA for its YORVIPATH medication, intended for adults with chronic hypoparathyroidism. This authorization, following the drug’s EU approval in November 2023, also grants the product orphan drug status, securing 10 years of market exclusivity in Great Britain for this indication. The success of YORVIPATH in Europe is part of Ascendis Pharma’s broader strategy to expand the treatment’s availability to other key markets, including the United States and Japan.
For further insights into ASND stock, check out TipRanks’ Stock Analysis page.
